Cancer-testis antigens: Unique cancer stem cell biomarkers and targets for cancer therapy
O Gordeeva - Seminars in cancer biology, 2018 - Elsevier
Cancer-testis antigens (CTAs) are considered as unique and promising cancer biomarkers
and targets for cancer therapy. CTAs are multifunctional protein group with specific …
and targets for cancer therapy. CTAs are multifunctional protein group with specific …
Cancer/testis antigens: from serology to mRNA cancer vaccine
Cancer/testis antigens (CTAs) are a group of tumor antigens expressed in numerous cancer
tissues, as well as in the testis and placental tissues. There are over 200 CTAs supported by …
tissues, as well as in the testis and placental tissues. There are over 200 CTAs supported by …
Resveratrol induces AMPK and mTOR signaling inhibition-mediated autophagy and apoptosis in multiple myeloma cells
R Ma, D Yu, Y Peng, H Yi, Y Wang… - Acta Biochimica et …, 2021 - academic.oup.com
Resveratrol, a natural compound extracted from the skins of grapes, berries, or other fruits,
has been shown to have anti-tumor effects against multiple myeloma (MM) via promoting …
has been shown to have anti-tumor effects against multiple myeloma (MM) via promoting …
[HTML][HTML] The expression, modulation and use of cancer-testis antigens as potential biomarkers for cancer immunotherapy
XF Li, P Ren, WZ Shen, X Jin… - American Journal of …, 2020 - ncbi.nlm.nih.gov
Cancer-testis antigens (CTA) are tumor antigens, present in the germ cells of testes, ovaries
and trophoblasts, which undergo deregulated expression in the tumor and malignant cells …
and trophoblasts, which undergo deregulated expression in the tumor and malignant cells …
Integration of IgA and IgG autoantigens improves performance of biomarker panels for early diagnosis of lung cancer
Lung cancer (LC) remains the leading cause of mortality from malignant tumors worldwide.
In our previous study, we surveyed both IgG and IgM-bound serological biomarkers and …
In our previous study, we surveyed both IgG and IgM-bound serological biomarkers and …
RETRACTED: Study on Attenuating Angiogenesis and Epithelial–Mesenchymal Transition (EMT) of Non-Small Cell Lung Carcinoma (NSCLC) by Regulating …
S Jiang, X Liu, D Li, M Yan, C Ju… - Technology in Cancer …, 2018 - journals.sagepub.com
Objective: To investigate the role of MAGE family member C2 in angiogenesis and epithelial–
mesenchymal transition of non-small cell lung carcinoma. Methods: The Cancer Genome …
mesenchymal transition of non-small cell lung carcinoma. Methods: The Cancer Genome …
Generation of TRIM28 Knockout K562 Cells by CRISPR/Cas9 Genome Editing and Characterization of TRIM28-Regulated Gene Expression in Cell Proliferation and …
YJ Chang, Z Kang, J Bei, SJ Chou, MYJ Lu… - International Journal of …, 2022 - mdpi.com
TRIM28 is a scaffold protein that interacts with DNA-binding proteins and recruits
corepressor complexes to cause gene silencing. TRIM28 contributes to physiological …
corepressor complexes to cause gene silencing. TRIM28 contributes to physiological …
Peptides and combination of peptides for use in immunotherapy against various cancers
M Andrea, T Weinschenk, S Colette, O Schoor… - US Patent …, 2019 - Google Patents
The present invention relates to peptides, proteins, nucleic acids and cells for use in
immunotherapeutic methods. In particular, the present invention relates to the …
immunotherapeutic methods. In particular, the present invention relates to the …
[HTML][HTML] Cancer testis antigens: Emerging therapeutic targets leveraging genomic instability in cancer
Cancer care has witnessed remarkable progress in recent decades, with a wide array of
targeted therapies and immune-based interventions being added to the traditional treatment …
targeted therapies and immune-based interventions being added to the traditional treatment …
Peptides and combination of peptides for use in immunotherapy against various cancers
M Andrea, T Weinschenk, S Colette, O Schoor… - US Patent …, 2019 - Google Patents
2016-12-30 Assigned to IMMATICS BIOTECHNOLOGIES GMBH reassignment IMMATICS
BIOTECHNOLOGIES GMBH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT …
BIOTECHNOLOGIES GMBH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT …